|
The average Mean Cell Survival (MCS) of the 17 LCLs at different drug concentrations, expressed as the Ratio of Maximum Achieved Plasma Concentration (RMAPC) |
||||||||||
| 64× dilution |
16× dilution |
4× dilution |
1× no dilution |
64× dilution |
16× dilution |
4× dilution |
1× no dilution |
|||
|
|
||||||||||
| Group 1 |
Vincristine |
Epirubicin |
||||||||
| RMAPC |
0.018 |
0.071 |
0.282 |
1.128 |
RMAPC |
0.003 |
0.012 |
0.046 |
0.184 |
|
| MCS |
81.498 |
46.541 |
20.776 |
18.995 |
MCS |
85.206 |
65.736 |
29.435 |
16.306 |
|
| SD |
27.995 |
25.737 |
15.258 |
12.209 |
SD |
15.548 |
23.394 |
13.593 |
11.314 |
|
|
|
||||||||||
| Paclitaxel |
Methotrexate |
|||||||||
| RMAPC |
0.020 |
0.081 |
0.326 |
1.303 |
RMAPC |
0.001 |
0.004 |
0.014 |
0.057 |
|
| MCS |
48.119 |
29.999 |
24.653 |
23.148 |
MCS |
76.618 |
44.824 |
32.924 |
29.314 |
|
| SD |
28.435 |
17.418 |
12.869 |
13.364 |
SD |
22.796 |
25.843 |
15.590 |
16.455 |
|
|
|
||||||||||
| Group 2 |
Gemcitabin |
Dactinomycin |
||||||||
| RMAPC |
0.035 |
0.140 |
0.561 |
2.242 |
RMAPC |
0.066 |
0.262 |
1.050 |
4.200 |
|
| MCS |
49.354 |
38.411 |
27.808 |
23.784 |
MCS |
86.206 |
54.700 |
20.520 |
16.465 |
|
| SD |
34.718 |
30.034 |
16.945 |
12.153 |
SD |
16.701 |
22.386 |
13.642 |
8.370 |
|
|
|
||||||||||
| 5-Flurouracil |
Vinorelbine |
|||||||||
| RMAPC |
0.012 |
0.047 |
0.188 |
0.752 |
RMAPC |
0.156 |
0.625 |
2.501 |
10.005 |
|
| MCS |
74.861 |
58.001 |
42.337 |
30.505 |
MCS |
82.833 |
42.823 |
25.176 |
24.683 |
|
| SD |
23.686 |
22.987 |
21.370 |
20.645 |
SD |
18.131 |
23.930 |
16.506 |
14.634 |
|
|
|
||||||||||
| Doxorubicin |
Daunorubicin |
|||||||||
| RMAPC |
0.028 |
0.112 |
0.447 |
1.789 |
RMAPC |
0.133 |
0.531 |
2.126 |
8.502 |
|
| MCS |
82.503 |
52.477 |
28.292 |
11.499 |
MCS |
83.171 |
61.159 |
25.940 |
20.439 |
|
| SD |
21.753 |
24.867 |
22.314 |
10.301 |
SD |
21.886 |
25.402 |
23.933 |
17.961 |
|
|
|
||||||||||
| Etoposide |
Docetaxel |
|||||||||
| RMAPC |
0.130 |
0.521 |
2.083 |
8.333 |
RMAPC |
0.260 |
1.042 |
4.166 |
16.665 |
|
| MCS |
56.281 |
35.375 |
25.315 |
16.778 |
MCS |
32.990 |
23.036 |
23.866 |
26.331 |
|
| SD |
21.045 |
19.983 |
15.497 |
11.166 |
SD |
22.690 |
17.587 |
16.810 |
19.810 |
|
|
|
||||||||||
| Group 3 |
Cytarabine |
6-Mercaptopurine |
||||||||
| RMAPC |
0.121 |
0.482 |
1.929 |
7.716 |
RMAPC |
0.543 |
2.170 |
8.680 |
34.720 |
|
| MCS |
87.321 |
79.450 |
48.255 |
40.124 |
MCS |
84.450 |
78.834 |
62.325 |
55.419 |
|
| SD |
17.396 |
22.850 |
26.423 |
26.315 |
SD |
22.147 |
16.514 |
29.820 |
32.858 |
|
|
|
||||||||||
| Oxaliplatin |
Cladribine |
|||||||||
| RMAPC |
0.020 |
0.081 |
0.325 |
1.301 |
RMAPC |
0.366 |
1.462 |
5.850 |
23.399 |
|
| MCS |
87.951 |
84.477 |
83.331 |
73.511 |
MCS |
102.832 |
101.241 |
72.497 |
52.237 |
|
| SD |
21.010 |
26.545 |
21.839 |
30.744 |
SD |
8.130 |
11.160 |
26.804 |
29.545 |
|
|
|
||||||||||
| Asparaginase |
Chlorambucil |
|||||||||
| RMAPC |
0.015 |
0.058 |
0.232 |
0.930 |
RMAPC |
2.646 |
10.586 |
42.342 |
169.370 |
|
| MCS |
92.021 |
91.570 |
90.371 |
82.978 |
MCS |
89.903 |
71.879 |
13.225 |
11.099 |
|
| SD |
13.718 |
13.222 |
18.153 |
15.919 |
SD |
17.578 |
26.506 |
10.994 |
7.527 |
|
|
|
||||||||||
| Cyclophosphamide |
Topotecan |
|||||||||
| RMAPC |
0.014 |
0.056 |
0.224 |
0.896 |
RMAPC |
6.194 |
24.777 |
99.107 |
396.429 |
|
| MCS |
86.670 |
93.412 |
89.498 |
84.041 |
MCS |
93.897 |
72.802 |
23.250 |
24.784 |
|
| SD |
21.910 |
18.833 |
17.832 |
17.920 |
SD |
19.406 |
21.275 |
16.659 |
21.380 |
|
|
|
||||||||||
| Ifosphamide |
Carboplatin |
|||||||||
| RMAPC |
0.009 |
0.037 |
0.147 |
0.588 |
RMAPC |
2.814 |
11.257 |
45.027 |
180.108 |
|
| MCS |
92.729 |
95.906 |
90.101 |
88.518 |
MCS |
91.805 |
79.175 |
77.962 |
52.322 |
|
| SD |
16.694 |
14.965 |
15.299 |
16.677 |
SD |
16.670 |
30.927 |
22.065 |
31.295 |
|
|
|
||||||||||
| Hydroxyurea |
Bleomycin |
|||||||||
| RMAPC |
0.031 |
0.124 |
0.496 |
1.984 |
RMAPC |
2.078 |
8.311 |
33.245 |
132.979 |
|
| MCS |
95.118 |
96.489 |
86.340 |
68.134 |
MCS |
90.007 |
88.553 |
82.168 |
69.803 |
|
| SD |
19.595 |
13.933 |
19.759 |
24.782 |
SD |
19.294 |
17.678 |
19.720 |
16.686 |
|
|
|
||||||||||
| Vinblastine |
Streptozotocin |
|||||||||
| RMAPC |
2.603 |
10.413 |
41.650 |
166.600 |
RMAPC |
no Cmax data was found |
||||
| MCS |
81.507 |
53.331 |
28.885 |
21.323 |
MCS |
95.430 |
92.335 |
89.919 |
87.805 |
|
| SD |
25.921 |
25.678 |
17.941 |
15.889 |
SD |
15.828 |
18.710 |
14.094 |
22.637 |
|
|
|
||||||||||
| Bortezomib |
MG-132 |
|||||||||
| RMAPC |
0.162 |
0.648 |
2.590 |
10.361 |
RMAPC |
not used in clinical practice |
||||
| MCS |
93.119 |
81.671 |
75.498 |
28.700 |
MCS |
87.345 |
96.374 |
88.097 |
27.045 |
|
| SD |
13.779 |
21.572 |
19.617 |
26.948 |
SD |
13.980 |
17.493 |
16.974 |
24.310 |
|
|
|
||||||||||
| Prednisolone |
||||||||||
| RMAPC |
4.8 |
19.23077 |
76.92308 |
307.6923 |
||||||
| MCS |
75.55877 |
76.25595 |
62.46537 |
37.23379 |
||||||
| SD |
4.647172 |
11.09091 |
13.97021 |
11.65414 |
||||||
|
Group 1. Highly effective drugs: RMAPC < 0.3; MCS < 30% Group 2. Partially effective drugs: RMAPC between 0.3 and 1, MCS < 60% Group 3. Ineffective drugs: RMAPC > 1 or MCS > 60% SD: standard deviation in mean cell survival | ||||||||||
Markasz et al. BMC Cancer 2006 6:265 doi:10.1186/1471-2407-6-265 |
||||||||||